Conducted during a webinar entitled ‘Critical Tasks of Site Monitors: Using a CTMS to Improve Efficiency’, Perceptive polled a broad cross section of biopharma industry professionals about the value of providing clinical research associates (CRAs) with access to a clinical trial management system (CTMS) to assist with monitoring and management activities.
Perceptive claims a CTMS allows CRAs to easily view patient data and keep up to date with the status of a trial, as well as helping inform the decision making process when planning site visits.
Results revealed that 89 per cent of respondents provided CRAs, with access to either a CTMS or other monitoring tool. According to Perceptive, the majority of these respondents combine other monitoring tools with a CTMS to improve efficiency across sites. Conversely, 11 per cent of respondents provided no such access to CTMS systems.
“As site management is a key part of the CRA role, providing CRAs with access to the cross-study and cross-site data available within a CTMS is vital,” said Liz Love, product manager of CTMS at Perceptive.
“There is a growing recognition across the industry that when CRAs use sophisticated eClinical technologies they are more efficient in site monitoring and management activities.”
Key milestones
In response to the survey’s findings, Boston, US-based Perceptive claims its IMPACT MySites module – part of its IMPACT CTMS – offers a complete site management and monitoring tool allowing users to view key trial milestones, recruitment progress and issue activity across all sites.
The company claims this approach allows CRAs to “seamlessly monitor workload and plan site visits, whether they are working online or offline.”
Love underscored the company's committment to providing targeted eClinical solutions aimed at helping simplify the trial process.
“At Perceptive, we are focused on enabling more effective centralised and field-based monitoring through our CTMS to support an increasingly mobile and globalised CRA workforce,” she said.